ADCY10 and glioblastoma: Notably, the effects evoked by these compounds were additive when co-administered to cells, suggesting that SAC is a potential candidate for the design of combined therapy for the treatment of GBM, which is supported by the lack of toxic effect of this antioxidant on primary astrocytes (Supplementary Material).